EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury
While ImmunityBio is involved in arbitration with Sorrento Therapeutics, which filed for bankruptcy this week to protect from the potential capital burden, the California biotech is pulling together $50 million.
EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury
EuMentis Therapeutics, a Boston-based biotech, has been handed an award from the US Department of Defense.